RAPT Therapeutics Inc
RAPT20.500USD
+2.500+13.89%
Handelsschluss 09/18, 16:00（ET）Kurse um 15 Minuten verzögert
338.27MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über RAPT Therapeutics Inc Unternehmen
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its drug discovery and development engine, it develops selective small molecules designed to modulate the critical immune responses underlying these diseases. Its lead inflammation drug candidate, zelnecirnon (RPT193), and its lead oncology drug candidate, tivumecirnon (FLX475), each target C-C motif chemokine receptor 4 (CCR4), a drug target that potentially has broad applicability in inflammatory diseases and oncology. Its inflammation drug candidate, zelnecirnon, is designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its oncology drug candidate, tivumecirnon, is designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors.
Unternehmensinformationen
BörsenkürzelRAPT
Name des UnternehmensRAPT Therapeutics Inc
IPO-datumOct 31, 2019
CEODr. Brian Wong, M.D., Ph.D.
Anzahl der mitarbeiter68
WertpapierartOrdinary Share
GeschäftsjahresendeOct 31
Addresse561 Eccles Ave
StadtSOUTH SAN FRANCISCO
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl94080
Telefon16504899000
Websitehttps://rapt.com/
BörsenkürzelRAPT
IPO-datumOct 31, 2019
CEODr. Brian Wong, M.D., Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Scott N. Braunstein, M.D.
Dr. Scott N. Braunstein, M.D.
Independent Director
Independent Director
--
--
Dr. Ashley Dombkowski, Ph.D.
Dr. Ashley Dombkowski, Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael F. Giordano, M.D.
Dr. Michael F. Giordano, M.D.
Independent Director
Independent Director
--
--
Dr. William (Bill) Ho, M.D., Ph.D.
Dr. William (Bill) Ho, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
--
--
Ms. Lori Lyons-Williams
Ms. Lori Lyons-Williams
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Brian Wong, M.D., Ph.D.
Dr. Brian Wong, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Dirk Brockstedt, Ph.D.
Dr. Dirk Brockstedt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Rodney K. B. Young
Mr. Rodney K. B. Young
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Linda Kozick
Ms. Linda Kozick
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Scott N. Braunstein, M.D.
Dr. Scott N. Braunstein, M.D.
Independent Director
Independent Director
--
--
Dr. Ashley Dombkowski, Ph.D.
Dr. Ashley Dombkowski, Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael F. Giordano, M.D.
Dr. Michael F. Giordano, M.D.
Independent Director
Independent Director
--
--
Dr. William (Bill) Ho, M.D., Ph.D.
Dr. William (Bill) Ho, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
--
--
Ms. Lori Lyons-Williams
Ms. Lori Lyons-Williams
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Tue, Aug 19
Aktualisiert: Tue, Aug 19
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Medicxi Ventures (UK) LLP
16.89%
OrbiMed Advisors, LLC
9.93%
TCG Crossover Management, LLC
9.89%
Foresite Capital Management, LLC
9.45%
RTW Investments L.P.
8.89%
Andere
44.94%
Aktionäre
Aktionäre
Anteil
Medicxi Ventures (UK) LLP
16.89%
OrbiMed Advisors, LLC
9.93%
TCG Crossover Management, LLC
9.89%
Foresite Capital Management, LLC
9.45%
RTW Investments L.P.
8.89%
Andere
44.94%
Aktionärstypen
Aktionäre
Anteil
Venture Capital
27.67%
Hedge Fund
23.02%
Private Equity
20.49%
Investment Advisor
16.50%
Investment Advisor/Hedge Fund
14.58%
Individual Investor
0.44%
Research Firm
0.31%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
295
16.40M
99.19%
-1.13M
2025Q1
309
29.14M
109.47%
+11.54M
2024Q4
309
140.52M
106.54%
+100.36M
2024Q3
304
31.22M
87.82%
-13.95M
2024Q2
305
33.18M
93.85%
-9.52M
2024Q1
295
33.76M
95.60%
-5.47M
2023Q4
282
36.46M
106.02%
-3.53M
2023Q3
281
36.40M
105.98%
-3.26M
2023Q2
295
35.63M
103.77%
-4.21M
2023Q1
301
34.71M
101.29%
-3.14M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Medicxi Ventures (UK) LLP
2.79M
16.9%
--
--
Mar 31, 2025
OrbiMed Advisors, LLC
1.64M
9.93%
--
--
Mar 31, 2025
TCG Crossover Management, LLC
1.64M
9.9%
-5.63K
-0.34%
Mar 31, 2025
Foresite Capital Management, LLC
1.56M
9.45%
--
--
Mar 31, 2025
RTW Investments L.P.
1.47M
8.89%
--
--
Mar 31, 2025
The Column Group LP
166.08K
1%
--
--
Mar 31, 2025
BVF Partners L.P.
1.15M
6.98%
--
--
Mar 31, 2025
Nantahala Capital Management, LLC
626.62K
3.79%
+471.18K
+303.13%
Mar 31, 2025
The Vanguard Group, Inc.
1.03M
6.26%
+668.30K
+182.32%
Mar 31, 2025
Adar1 Capital Management LLC
746.35K
4.51%
+599.56K
+408.45%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
